Over 12 months, STRATA Skin Sciences, Inc. saw more selling than buying from its insiders — purchases of about $7,028 against sales of $19,000.
Biggest single buyer: Rubinstein Samuel, Director, with roughly $3,993.
Quarter by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Rubinstein Samuel | Director | Sell | 7,200 | $1.34 | $10K | SEC |
| Nov 18, 2025 | Rubinstein Samuel | Director | Sell | 5,500 | $1.32 | $7K | SEC |
| Nov 18, 2025 | Rubinstein Samuel | Director | Sell | 1,394 | $1.36 | $2K | SEC |
| Nov 18, 2025 | Rubinstein Samuel | Director | Buy | 2,168 | $1.40 | $3K | SEC |
| Nov 18, 2025 | Rubinstein Samuel | Director | Buy | 2,832 | $1.41 | $4K | SEC |
| Jul 17, 2024 | Geiger Uri | Director | Buy | 230,573 | $3.14 | $724K | SEC |
| Jul 17, 2024 | Accelmed Growth Partners (AGP) Ltd | 10% Owner | Buy | 230,573 | $3.14 | $724K | SEC |
| Jul 17, 2024 | Rafaeli Dolev | CEO | Buy | 19,100 | $3.14 | $60K | SEC |
| Dec 5, 2023 | Gov Shmuel | COO | Buy | 4,800 | $0.47 | $2K | SEC |
| Dec 5, 2023 | Gov Shmuel | COO | Buy | 14,338 | $0.44 | $6K | SEC |
| Dec 5, 2023 | Gov Shmuel | COO | Buy | 562 | $0.45 | $253 | SEC |
| Dec 5, 2023 | Gov Shmuel | COO | Buy | 300 | $0.46 | $138 | SEC |
| Nov 20, 2023 | Rubinstein Samuel | Director | Sell | 1,000 | $0.32 | $320 | SEC |
| Aug 18, 2023 | 22NW GP, Inc. | 10% Owner | Buy | 1,853,056 | $0.55 | $1.0M | SEC |
| Aug 11, 2023 | Lesovitz Christopher | CFO | Buy | 5,151 | $0.68 | $4K | SEC |
In the last 12 months STRATA Skin Sciences, Inc. insiders made open-market purchases worth about $7,028 and sales worth about $19,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in SSKN was filed on 2025-11-18.
No congressional trades in SSKN were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).